Study Of Detection Of Serum CXCL10 In Vitiligo Patients
El- Rifaie, A., Naguib, R., Rashed, L., Ahmed, M. (2022). Study Of Detection Of Serum CXCL10 In Vitiligo Patients. EKB Journal Management System, 3(1), 37-56. doi: 10.21608/ejmr.2022.216156
Abd-El Aziz El- Rifaie; Rehab Mohamed Naguib; Laila Ahmed Rashed; Marwa Fathelbab Ahmed. "Study Of Detection Of Serum CXCL10 In Vitiligo Patients". EKB Journal Management System, 3, 1, 2022, 37-56. doi: 10.21608/ejmr.2022.216156
El- Rifaie, A., Naguib, R., Rashed, L., Ahmed, M. (2022). 'Study Of Detection Of Serum CXCL10 In Vitiligo Patients', EKB Journal Management System, 3(1), pp. 37-56. doi: 10.21608/ejmr.2022.216156
El- Rifaie, A., Naguib, R., Rashed, L., Ahmed, M. Study Of Detection Of Serum CXCL10 In Vitiligo Patients. EKB Journal Management System, 2022; 3(1): 37-56. doi: 10.21608/ejmr.2022.216156

Study Of Detection Of Serum CXCL10 In Vitiligo Patients

Egyptian Journal of Medical Research
Article 4, Volume 3, Issue 1, January 2022, Page 37-56  XML PDF (491.85 K)
Document Type: Original Article
DOI: 10.21608/ejmr.2022.216156
View on SCiNiTO View on SCiNiTO
Authors
Abd-El Aziz El- Rifaie1; Rehab Mohamed Naguib1; Laila Ahmed Rashed2; Marwa Fathelbab Ahmed3
1Dermatology department, Faculty of Medicine, Beni-Suef University, Egypt
2Medical Biochemistry & Molecular Biology Department, Faculty of Medicine,Cairo University,Egypt
3Dermatology department, Maghagha General Hospital, Ministry of Health, Egypt
Abstract
The goal of this study was to detect the level of CXCL10 in the serum of  the vitiligo patients as compared to the normal control persons to investigate the possible role of CXCL10 in the pathogenesis of  this disease. The present study included 30 Egyptian vitiligo patients, their age ranged from (20 to 50 years). They were recruited fromDermatology outpatient clinic at Beni-Suef University hospital. Thirty unrelated apparent healthy controls with similar demographic (matched age and sex) were taken during the period from (1st May 2018 to 1st May 2019).5ml blood sample was taken from patients and controls and  was left to clot for 30 minutes then serum was separated  by centrifugation and kept frozen at -80c till analysis of CXCL10 by ELISA. The patients and controls were subjected to estimation of the serum level of CXCL10. The result of the study showed that  increased levels of CXCL10 in the vitiligo patients when compared to controls and the  patients in the progressive stage showed higher expression of CXCL10 than those in the stable stage,  suggesting a mechanistic  role of CXCL10 in vitiligo.
Keywords
Vitiligo; T cell immune response; IFN-γ; CXCL-10
References
  1. Ezzedine K, Lim HW, Suzuki T,  Katayama I, Hamzavi  I, Lan CCE, et al. Revised classification / nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res 2012; 25(3): 1–13. 
  2. Ibrahim A, El-Rifaieb  AE, Mostafa Y, Ahmed  L and Gamal E.Demographic Characteristics of Vitiligo Patients in Beni-Suef University Hospital. Egyptian Journal of Medical Research (EJMR) .article 2,volume 1,Issue 1. 2020; 17-28.
  3. Namian  AM, Shahbaz  S and Samanpoor  R.Association of interferon-gamma and tumor necrosis factor-alpha polymorphism with susceptibility to vitiligo in Iranian patients. Arch Dermatol Res 2008;301: 21.
  4. Griffith JW, Sokol CL and Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol 2014; 32:659-702.
  5. Sokol CL and Luster AD. The chemokine system in innate immunity.Cold Spring Harb Perspect boil 2015; 7(5):101- 6.
  6. Keeley EC, Mehrad B and Strieter RM. Chemokines as mediators of tumor angiogenesis and neovascularization. Exp  Cell  Res 2011; 317(5): 685-90.
  7. Martins-Green M, Petreaca M and Wang L. Chemokines and their receptors are key players in the orchestra  that regulates wound  healing. Advances in Wound Care 2013; 2(7): 327 – 47.
  8. Wang N, Liu W, Zheng Y, Wang S, Yang B, Li  M, et al. CXCL1 derived from tumor associated macrophages promotes breast cancer metastasis via activating NF-kB/SOX4 signalling. Cell death & diseases 2018; 9(9):1-18.
  9. Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, et al. CXCL9, CXCL10, CXCL11/ CXCR3 axis for immune activation-a target for novel cancer therapy. Cancer treatment reviews 2018; 63: 40-47.
  10. Manga P, Elbuluk N and Orlow SJ. Recent advances in understanding vitiligo. F1000 Res 2016; 5: 100-5.
  11. Laddha NC, Dwivedi M and Begum R. Increased tumor necrosis factor (TNF)-alpha and its promoter polymorphisms correlate with disease progression and higher susceptibility towards vitiligo. PLo SONE 2012 ; 7: 52298.
  12. Dwivedi M, Laddha  NC, Shah K, Shah BJ and Begum  R. Involvement of interferon-gamma genetic variants and intercellular adhesion molecule-1 in onset and progression of   generalized vitiligo. J Interferon Cytokine Res 2013; 33(11): 646–59.
  13. Annunziato  F, Cosmi L, Liotta F, Maggi E and Romagnani  S. Human Th1 dichotomy :origin, phenotype and biologic activities. Immunology 2015; 144: 343–351.
  14. Antonelli A, Ferrari SM, Giuggioli D, Ferrannini E, Ferri  C and Fallahi P. The Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmunity Reviews 2014; 13: 272–80.
  15. Antonelli A, Ferrari  SM and  Fallahi  P. The role of the Th1 Chemokine CXCL10 in Vitiligo. Annals of  Translational  Medicine 2015; 3:1-16.
  16. Rashighi M, Agarwal P, Richmond JM, Harris TH, Dresser K, Su MW, et al.CXCL10 is critical for progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med 2014; 6: 223-23.
  17. Wang X, Wang Q, Wu J, Jiang M, Chen L, Zhang CF, et al. Increased expression of CXCR3 and its ligands in vitiligo patients and CXCL10 as a potential clinical marker for vitiligo. Br J Dermatol 2016; 174(6): 1318–1326.
  18. Boniface K, Seneschal J, Picardo M and Taieb A. Vitiligo: focus on clinical aspects,immunopathogenesis  and therapy. clinical reviews in allergy & immunology 2018; 54(1): 52 -67.
  19. Bhor U and Pande S. Scoring  systems in dermatology. Indian J Der­matol Venereol Leprol 2006; 72: 315-21.
  20. Rothstein B,  Joshipura D, Saraiya A, Abdat  R,  Ashkar  H,  Turkowski  Y, et al. Treatment of vitiligo with topical janus kinase inhibitor ruxolitinib, Journal of American Academy  of Dermatology 2017; 76(6):1054-1060.
  21. Rezaei  N, Gavalas NG, Weetman AP and Kemp EH. Autoimmunity as an etiological factor in vitiligo. J Europ Acad Derm Venereol 2007; 21: 865-76.
  22. Li S, Zhu G, yang  Y, Jian Z, Guo S, Dai W, et al. Oxidative stress drives CD8+ T-cell skin trafficking in patients with vitiligo through CXCL16 upregulation by activating the unfolded protein response in keratinocytes. Journal of Allergy and clinical Immunology 2017; 140(1): 177-189.
  23. Van den Boorn JG, Konijnenberg D, Dellemijn TA, Van der Veen JP, Bos JD and Melief CJ. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol 2009; 129: 2220–32.
  24. Vazirinejad R, Ahmadi Z,  Kazemi  Arababadi  M,  Hassanshahi G and Kennedy D. Biological functions, structure and sources of CXCL10 and its outstanding part in the pathophysiology of multiple  sclerosis. Neuro Immuno Modulation 2014; 21(6): 322–30.
  25. Groom JR and Luster AD. CXCR3 ligands : redundant, collaborative and antagonistic functions. Immunol Cell Biol 2011; 89:207 -15.
  26. Harris JE, Harris TH, Wherry EJ, Hunter CA and Turka LA. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8+ T-cell accumulation in the skin. J Invest Dermatol 2012; 132(7): 1869-76.
  27. Richmond JM, Bangari DS, Essien, KI, Currimbhoy SD, Groom JR,  Pandya AG,  et al. Keratinocyte derived chemokines orchestrate T-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease. J Invest Dermatol 2017;137(2): 350–358.
 

 

 

Statistics
Article View: 335
PDF Download: 411